Lovero R, Losurdo G, La Fortezza RF, Terracciano F, et al. Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2021;32:201-207.
PMID: 33369956